<SEC-DOCUMENT>0000939767-17-000068.txt : 20170501
<SEC-HEADER>0000939767-17-000068.hdr.sgml : 20170501
<ACCEPTANCE-DATETIME>20170501160847
ACCESSION NUMBER:		0000939767-17-000068
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170501
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170501
DATE AS OF CHANGE:		20170501

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXELIXIS, INC.
		CENTRAL INDEX KEY:			0000939767
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				043257395
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0102

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30235
		FILM NUMBER:		17800805

	BUSINESS ADDRESS:	
		STREET 1:		210 E. GRAND AVE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		6508377000

	MAIL ADDRESS:	
		STREET 1:		210 E. GRAND AVE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS INC
		DATE OF NAME CHANGE:	20000207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20000106
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>exel8-kq12017earningsrelea.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sA64A00A06C562AD2685A169C6DBAE375"></a></div><div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Washington, D.C. 20549</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:300px;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:300px;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-top:2px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 8-K</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CURRENT REPORT </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PURSUANT TO SECTION 13 OR 15(d) OF THE </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECURITIES EXCHANGE ACT OF 1934 </font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Date of Report (Date of earliest event reported): </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">May&#160;1, 2017</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:24pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:300px;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:300px;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-top:2px;text-align:center;font-size:24pt;"><font style="font-family:inherit;font-size:24pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(Exact name of registrant as specified in its charter)</font></div></td></tr></table></div></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">0-30235</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">04-3257395</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;text-indent:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(State or Other Jurisdiction  <br>of Incorporation)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;text-indent:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(Commission  <br>File Number)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;text-indent:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(IRS Employer  <br>Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">210 East Grand Ave.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">South San Francisco, California 94080</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(Address of principal executive offices) (Zip Code)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(650) 837-7000</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(Registrant&#8217;s telephone number, including area code) </font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">see</font><font style="font-family:inherit;font-size:10pt;">&#32;General Instruction A.2. below): </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:1px;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:1px;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:1px;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:1px;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). Emerging growth company </font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;padding-top:24px;text-align:center;font-size:4pt;"><font style="font-family:inherit;font-size:4pt;">&#160;</font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s5119F8AE098A01A12F95169C6DD8C398"></a></div><div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:14%;"></td><td style="width:86%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2.02</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of Operations and Financial Condition.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On </font><font style="font-family:inherit;font-size:10pt;">May&#160;1, 2017</font><font style="font-family:inherit;font-size:10pt;">, Exelixis issued a press release announcing its financial results for the quarter ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, and providing a corporate update. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information in this Item 2.02, including the exhibit hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Exelixis, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:14%;"></td><td style="width:86%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Statements and Exhibits.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:87.3931623931624%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:7%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(d)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibits.</font></div></td></tr></table></div></div><div style="line-height:100%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Number</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exhibit Description</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1&#160;&#160;&#160;&#160;Press Release issued </font><font style="font-family:inherit;font-size:10pt;">May&#160;1, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sC5D16C301D67E13EF0AA169C6E0AB42D"></a></div><div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:9%;"></td><td style="width:23%;"></td><td style="width:6%;"></td><td style="width:53%;"></td><td style="width:9%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXELIXIS, INC.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May&#160;1, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:12px;padding-bottom:1px;padding-right:2px;"><div style="vertical-align:middle;padding-bottom:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">/s/ J</font><font style="font-family:inherit;font-size:8pt;vertical-align:middle;">EFFREY</font><font style="font-family:inherit;font-size:10pt;vertical-align:middle;">&#160;J. H</font><font style="font-family:inherit;font-size:8pt;vertical-align:middle;">ESSEKIEL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Jeffrey J. Hessekiel</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Vice President, General Counsel and Secretary</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:33px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s88023285788881EB0556169C6E326277"></a></div><div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:174%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">EXHIBIT INDEX</font></div><div style="line-height:120%;padding-top:14px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:14px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Number</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit Description</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1&#160;&#160;&#160;&#160;Press Release issued </font><font style="font-family:inherit;font-size:10pt;">May&#160;1, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exelexhibit991exelq12017.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s8C28C42D22157692F34E169C6D103DBE"></a></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:660px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><img src="exellogo2017q1.gif" alt="exellogo2017q1.gif" style="height:126px;width:200px;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contacts:</font></div><div style="line-height:120%;text-align:right;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Chris Senner</font></div><div style="line-height:120%;text-align:right;padding-left:18px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Chief Financial Officer</font></div><div style="line-height:120%;text-align:right;padding-left:144px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Exelixis, Inc.</font></div><div style="line-height:120%;text-align:right;padding-left:144px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(650) 837-7240</font></div><div style="line-height:120%;text-align:right;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0000ff;font-style:italic;text-decoration:underline;">csenner@exelixis.com</font></div><div style="line-height:120%;text-align:right;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Susan Hubbard</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Executive Vice President, </font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Public Affairs and </font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Investor Relations</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Exelixis, Inc.</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(650) 837-8194</font></div><div style="line-height:120%;text-align:right;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0000ff;font-style:italic;text-decoration:underline;">shubbard@exelixis.com</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXELIXIS ANNOUNCES FIRST QUARTER 2017 FINANCIAL RESULTS </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AND PROVIDES CORPORATE UPDATE</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">- Cabozantinib Franchise Net Product Revenues of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">$68.9 Million</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">, Total Revenues of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">$80.9 Million</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;-</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">- Achieves Profitability with Net Income of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">$16.7 Million</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">, Diluted EPS of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">$0.05</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;per Share -</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">- Conference Call and Webcast Today at 5:00 PM Eastern Time -</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SOUTH SAN FRANCISCO, CA - </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">May&#160;1, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;- Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2017 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2017, Exelixis is focused on maximizing the opportunity for its two internally-discovered compounds, cabozantinib and cobimetinib, to improve care and outcomes for people with cancer around the world. The company&#8217;s foremost priority is the ongoing U.S. launch of CABOMETYX&#8482; (cabozantinib) tablets as a treatment for patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy. During the first quarter of 2017, CABOMETYX generated </font><font style="font-family:inherit;font-size:10pt;">$62.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in net product revenue, while COMETRIQ</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(cabozantinib) capsules for the treatment of patients with progressive, metastatic medullary thyroid cancer generated an additional </font><font style="font-family:inherit;font-size:10pt;">$6.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in net product revenue, for a combined </font><font style="font-family:inherit;font-size:10pt;">$68.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in net product revenue for the cabozantinib franchise. In addition, Exelixis progressed its preparations to submit a supplemental New Drug Application (sNDA) for cabozantinib as a treatment for previously untreated patients with advanced RCC based on the positive data from the CABOSUN randomized phase 2 trial. Finally, Exelixis and its partner Genentech, a member of the Roche Group, are continuing to co-promote COTELLIC</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(cobimetinib) in combination with vemurafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E mutation in the United States. Genentech continues to advance the cobimetinib clinical development program, and recently announced that IMblaze370, the phase 3 pivotal trial evaluating the combination of cobimetinib and atezolizumab in third-line advanced or metastatic colorectal cancer, achieved full enrollment in the first quarter of 2017. Two other </font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">phase 3 pivotal trials of combination regimens including cobimetinib are planned or underway in forms of advanced melanoma.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#8220;The Exelixis team&#8217;s progress this quarter is a launching point from which to build throughout 2017 as we work diligently to position the company as a sustainable business focused on improving the treatment of cancer for patients on a global basis,&#8221; said Michael M. Morrissey, Ph.D., President and Chief Executive Officer of Exelixis. &#8220;During the first quarter of 2017, we reached the important milestone for our shareholders of achieving profitability based on operations. In addition, we further advanced cabozantinib&#8217;s commercialization and clinical development through our ongoing strong execution on the CABOMETYX U.S. launch, made additional progress in our preparations to submit a sNDA for previously untreated patients with advanced RCC, entered into important clinical development collaborations that will evaluate cabozantinib in combination with leading immunotherapies, and granted Japanese rights to a new cabozantinib partner, Takeda.&#8221;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dr. Morrissey continued: &#8220;Our partner Genentech moved cobimetinib, the second Exelixis-discovered compound, forward during the quarter as well, with the completion of enrollment in IMblaze370 in patients with advanced colorectal cancer. At Exelixis, we are focused on continuing to lay the groundwork for the future, including repaying our remaining debt this summer, planning to fund the company&#8217;s growth from its operations, and assessing in-licensing opportunities and resuming internal drug discovery. We are committed to a plan that involves measured and judicious growth to put the company in the best position to help patients and build long-term value.&#8221;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Cabozantinib Highlights</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Strong Growth in Cabozantinib Franchise Net Revenues. </font><font style="font-family:inherit;font-size:10pt;">Cabozantinib generated </font><font style="font-family:inherit;font-size:10pt;">$68.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in net product revenue during the first quarter of 2017, an increase of </font><font style="font-family:inherit;font-size:10pt;">33 percent</font><font style="font-family:inherit;font-size:10pt;">&#32;from the fourth quarter of 2016 and an increase of </font><font style="font-family:inherit;font-size:10pt;">657 percent</font><font style="font-family:inherit;font-size:10pt;">&#32;year-over-year. The year-over-year increase was driven primarily by the U.S. introduction of CABOMETYX following FDA approval in April 2016 as a treatment for patients with advanced RCC who have received prior anti-angiogenic therapy.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Partnership with Takeda for Japanese Commercialization and Development. </font><font style="font-family:inherit;font-size:10pt;">In January 2017, Exelixis and Takeda jointly announced an exclusive licensing agreement for the commercialization and further development of cabozantinib in Japan, including rights to CABOMETYX and COMETRIQ. Under the terms of the agreement, Exelixis received a $50.0 million non-refundable upfront payment. Exelixis is eligible to receive development, regulatory, and first-sales milestones of $95.0 million for the first three planned indications. In addition, Exelixis will be eligible to receive royalties on sales by Takeda. Takeda will be responsible for 20 percent of the costs associated with the global cabozantinib development plan&#8217;s current and future trials, provided Takeda opts in to participate in such future trials, and 100 percent of costs associated with the cabozantinib development activities that are exclusively for the benefit of Japan.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Phase 1 Trial Results in Combination with Nivolumab and Ipilimumab in Advanced Genitourinary Tumors. </font><font style="font-family:inherit;font-size:10pt;">At the ASCO Genitourinary Cancers Symposium in February 2017, investigators presented data from the phase 1 trial of cabozantinib in combination with nivolumab, with and without ipilimumab, in patients with previously treated genitourinary tumors including metastatic urothelial carcinoma and RCC. Data from this NCI-CTEP-sponsored study have informed the design of Exelixis and Bristol-Myers Squibb Company&#8217;s (BMS) planned phase 3 pivotal trial of cabozantinib in combination with these therapies in first-line RCC, which is expected to start later this year. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaborations for Late-Stage Development in Combination with Immunotherapies. </font><font style="font-family:inherit;font-size:10pt;">In February 2017, Exelixis announced agreements with BMS and Roche to collaborate on the development of cabozantinib in combination with immunotherapy agents. Exelixis and BMS announced their intent to collaborate on the evaluation of cabozantinib in combination with Opdivo</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(nivolumab) alone or in combination with Yervoy</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(ipilimumab) in a phase 3 trial in first-line RCC, and potentially in other tumor types including hepatocellular carcinoma (HCC) and bladder cancer. These studies are anticipated to begin in 2017. The collaborations build upon previously published preclinical and clinical data that underscore the scientific rationale for combining cabozantinib with immunotherapies, and provide the resources and collaborative framework to evaluate the potential for cabozantinib combination regimens to benefit patients with a variety of cancers. Separately, Exelixis and Roche will collaborate to initiate the evaluation of cabozantinib in combination with Tecentriq</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(atezolizumab), an anti-PD-L1 antibody, in patients with advanced </font></div><div><br></div><div><div style="line-height:120%;padding-left:30px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RCC or bladder cancer. Ipsen has opted in to participate in the phase 3 pivotal trial in first-line advanced RCC with BMS and to participate in the study with Roche, and will have access to the results to support potential future regulatory submissions and for potential future development in its territories.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Continued Progress on Filing in Previously Untreated Advanced RCC. </font><font style="font-family:inherit;font-size:10pt;">During the first quarter,</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">Exelixis continued to make progress on its sNDA for cabozantinib as a treatment for previously untreated advanced RCC, and the company remains on track to complete the filing in the third quarter of 2017. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Orphan Drug Designation for HCC; Update on CELESTIAL Timelines. </font><font style="font-family:inherit;font-size:10pt;">In March, the U.S. Food &amp; Drug Administration (FDA) granted cabozantinib orphan drug designation for the treatment of HCC. A phase 3 pivotal trial (CELESTIAL) of cabozantinib is ongoing in patients with advanced HCC, and Exelixis is tracking events closely and now anticipates the second interim analysis at 75 percent of the events required will be completed in the second half of 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Cobimetinib Highlights</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">IMblaze370 in Advanced Colorectal Cancer Completes Enrollment. </font><font style="font-family:inherit;font-size:10pt;">Roche and Genentech recently announced that IMblaze370, the phase 3 pivotal trial evaluating the combination of cobimetinib and atezolizumab in third-line advanced or metastatic colorectal cancer, achieved full enrollment in the first quarter of 2017. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Two Pivotal Trials in Melanoma to Be Underway in 2017. </font><font style="font-family:inherit;font-size:10pt;">In addition to the progress with IMblaze370, Roche has made it public that IMspire150 TRILOGY, which evaluates the combination of cobimetinib, atezolizumab, and vemurafenib in first-line BRAF V600 mutation-positive metastatic or unresectable locally advanced melanoma, enrolled its first patient in January 2017. IMspire170, a planned pivotal trial of cobimetinib and atezolizumab vs. pembrolizumab in first-line BRAF wild-type metastatic or unresectable locally advanced melanoma, is expected to enroll its first patient in the second quarter of this year. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Update on Dispute between Exelixis and Genentech. </font><font style="font-family:inherit;font-size:10pt;">In January 2017, Exelixis announced that Genentech, a member of the Roche Group, had withdrawn its counterclaim against Exelixis in the ongoing JAMS arbitration concerning alleged breaches of the parties&#8217; collaboration agreement. Genentech had asserted a counterclaim for breach of contract, which sought monetary damages and interest related to cost allocations under the collaboration agreement. When notifying the arbitral panel, and Exelixis, of this unilateral action, Genentech further stated that it is changing the manner in which it allocates promotional expenses of the COTELLIC</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></font><font style="font-family:inherit;font-size:10pt;">plus Zelboraf</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(vemurafenib) combination therapy. Genentech&#8217;s revised allocation applies retrospectively and prospectively and substantially reduces Exelixis&#8217; exposure to costs associated with promotion of the COTELLIC</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></font><font style="font-family:inherit;font-size:10pt;">plus Zelboraf combination in the United States. Notwithstanding Genentech&#8217;s change of approach, other significant issues remain in dispute between the parties. As a result, we will continue to press our position before the arbitral panel to obtain a just resolution of these claims. The ultimate outcome and timing of the arbitration is difficult to predict.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Corporate Highlights</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Reduced Indebtedness Through Repayment of Silicon Valley Bank Loan. </font><font style="font-family:inherit;font-size:10pt;">In late March 2017, Exelixis repaid all amounts outstanding under its term loan with Silicon Valley Bank initiated in 2010 and which was due for repayment on May 31, 2017. The payment included </font><font style="font-family:inherit;font-size:10pt;">$80.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in principal plus </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in accrued and unpaid interest. The company also plans to repay the Deerfield Notes, a series of Convertible Secured Notes issued to entities associated with Deerfield Management Company, L.P. due July 1, 2018. Exelixis has designated the Deerfield Notes a Current Liability given its ability and intent to retire them on or about July 1, 2017, one year ahead of their maturity date. As of March 31, 2017, the carrying balance on the Deerfield Notes was </font><font style="font-family:inherit;font-size:10pt;">$113.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;with the total of $124.9 million due at maturity. Retiring the Deerfield Notes one year ahead of their maturity date will provide the company a savings of approximately $12 million in interest expense, net of the termination fee.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cabozantinib and Cobimetinib Data Presentations at the 2017 ASCO Annual Meeting.</font><font style="font-family:inherit;font-size:10pt;">&#32;Exelixis-discovered compounds will be the subject of 13 presentations, including further analysis of the METEOR study in advanced RCC as well as updated results from the phase 1b combination trial of cabozantinib plus immunotherapy in genitourinary tumors. Additional cabozantinib data presentations will include results from trials in endometrial cancer and uterine&#160;carcinosarcoma.&#160;Cobimetinib data will include updates from the early stage combination trials of </font></div><div><br></div><div><div style="line-height:120%;padding-left:30px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">cobimetinib plus atezolizumab, and plus atezolizumab and vemurafenib, which have informed the design of several of Roche&#8217;s ongoing or planned phase 3 pivotal trials.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">2017 Financial Guidance</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company is reiterating its previously provided guidance that total costs and operating expenses for the full year will be between $290 million and $310 million.&#160; This guidance includes approximately $25 million of non-cash costs and expenses related primarily to stock-based compensation expense.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">First Quarter 2017 Financial Results</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total revenues </font><font style="font-family:inherit;font-size:10pt;">for the quarter ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;">$80.9 million</font><font style="font-family:inherit;font-size:10pt;">, compared to </font><font style="font-family:inherit;font-size:10pt;">$15.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the comparable period in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. Total revenues include </font><font style="font-family:inherit;font-size:10pt;">$68.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of net product revenues compared to </font><font style="font-family:inherit;font-size:10pt;">$9.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the comparable period in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. The increase in net product revenues primarily reflects the impact of the commercial launch of CABOMETYX in late April 2016. Total revenues also include </font><font style="font-family:inherit;font-size:10pt;">$12.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of collaboration revenues compared to </font><font style="font-family:inherit;font-size:10pt;">$6.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the comparable period in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. Collaboration revenues for the quarter ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;include </font><font style="font-family:inherit;font-size:10pt;">$4.5 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$2.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;earned under our collaboration agreements with Ipsen, Takeda and Genentech, respectively, and </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in contract revenues from a milestone payment received from BMS related to its ROR gamma program. In comparison, during the three months ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, collaboration revenues include </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in collaboration revenue under our collaboration agreements with Ipsen and Genentech, respectively, and </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in contract revenues from a milestone payment received from Merck related to its worldwide license of our PI3K-delta program. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research and development expenses</font><font style="font-family:inherit;font-size:10pt;">&#32;for the quarter ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;">$23.2 million</font><font style="font-family:inherit;font-size:10pt;">, compared to </font><font style="font-family:inherit;font-size:10pt;">$28.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the comparable period in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. The decrease in research and development expenses were primarily a result of decreases in clinical trial costs for METEOR, the company&#8217;s phase 3 trial in advanced RCC, and share-based compensation; those decreases were partially offset by an increase in personnel related expenses resulting from an increase in headcount predominantly associated with the build-out of the Exelixis medical affairs organization. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Selling, general and administrative expenses</font><font style="font-family:inherit;font-size:10pt;">&#32;for the quarter ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;">$34.3 million</font><font style="font-family:inherit;font-size:10pt;">, compared to </font><font style="font-family:inherit;font-size:10pt;">$34.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the comparable period in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. The decrease in selling, general and administrative expenses was primarily a result of decreases in marketing costs due to a decrease in losses under the collaboration agreement with Genentech and stock-based compensation; those decreases were almost entirely offset by increases in personnel expenses resulting from an increase in headcount connected with the build-out of the Exelixis U.S. commercial organization and an increase in legal costs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other expense, net </font><font style="font-family:inherit;font-size:10pt;">for the quarter ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;was a net expense of </font><font style="font-family:inherit;font-size:10pt;">$3.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$10.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the comparable period in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. The decrease in other expense, net, was primarily due to a decrease in interest expenses as a result of the 2016 conversions and redemption of the 4.25 percent Convertible Subordinated Notes due 2019.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net income </font><font style="font-family:inherit;font-size:10pt;">for the quarter ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$16.7 million</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">$0.06</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, basic, and </font><font style="font-family:inherit;font-size:10pt;">$0.05</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, diluted, compared to a net loss of </font><font style="font-family:inherit;font-size:10pt;">$(59.2) million</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">$(0.26)</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, basic and diluted, for the comparable period in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. The decrease in net loss for the quarter ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;was primarily due to the increase in net product and collaboration revenues and the decrease in operating and interest expenses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash </font><font style="font-family:inherit;font-size:10pt;">and cash equivalents, short- and long-term investments and long-term restricted cash and investments totaled </font><font style="font-family:inherit;font-size:10pt;">$475.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;at </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, as compared to </font><font style="font-family:inherit;font-size:10pt;">$479.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exelixis adopted a 52- or 53-week fiscal year that generally ends on the Friday closest to December 31</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">st</sup></font><font style="font-family:inherit;font-size:10pt;">. For convenience, references in this press release as of and for the fiscal periods ended&#160;March 31, 2017, December 30, 2016&#160;and April 1, 2016 are indicated as being as of and for the periods ended&#160;March 31, 2017, December 31, 2016 and March 31, 2016, respectively. </font></div><div><br></div><div><div style="line-height:120%;padding-left:30px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Conference Call and Webcast</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exelixis management will discuss the company&#8217;s financial results for first quarter of 2017 and provide a general business update during a conference call beginning at 5:00 p.m. EDT/2:00 p.m. PDT today, Monday, May 1, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To access the webcast link, log onto </font><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">www.exelixis.com</font><font style="font-family:inherit;font-size:10pt;">&#32;and proceed to the Event Calendar page under Investors &amp; Media. Please connect to the company&#8217;s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call (855) 793-2457 (domestic) or (631) 485-4921 (international) and provide the conference call passcode 3901622 to join by phone.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A telephone replay will be available until 11:59 p.m. EDT on Wednesday, May 3, 2017. Access numbers for the telephone replay are: (855) 859-2056 (domestic) and (404) 537-3406 (international); the passcode is 3901622. A webcast replay will also be archived on </font><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">www.exelixis.com</font><font style="font-family:inherit;font-size:10pt;">&#32;for one year.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">About Exelixis</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exelixis, Inc. (Nasdaq: EXEL) is a biopharmaceutical company committed to the discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. Since its founding in 1994, three products discovered at Exelixis have progressed through clinical development, received regulatory approval, and entered the marketplace. Two are derived from cabozantinib, an inhibitor of multiple tyrosine kinases including MET, AXL and VEGF receptors: CABOMETYX&#8482; tablets approved for previously treated advanced kidney cancer and COMETRIQ</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;capsules approved for progressive, metastatic medullary thyroid cancer. The third product, COTELLIC</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, is a formulation of cobimetinib, a selective inhibitor of MEK, is marketed under a collaboration with Genentech (a member of the Roche Group), and is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a variety of forms of cancer and are the subjects of broad clinical development programs. For more information on Exelixis, please visit </font><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">www.exelixis.com</font><font style="font-family:inherit;font-size:10pt;">&#32;or follow @ExelixisInc on Twitter.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Forward-Looking Statements</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This press release contains forward-looking statements, including, without limitation, statements related to: Exelixis&#8217; focus on maximizing the opportunity for cabozantinib and cobimetinib to help patients with cancer around the world; continued progress towards submission of a sNDA in the third quarter for cabozantinib as a treatment for previously untreated patients with advanced RCC based on the CABOSUN trial; continued co-promotion, with Genentech, of cobimetinib in combination with vemurafenib for melanoma in the U.S.; Genentech&#8217;s continued expansion and advancement of its development program for cobimetinib and the planned initiation of its phase 3 pivotal trial of cobimetinib and atezolizumab vs. pembrolizumab in first-line BRAF wild-type advanced melanoma; Exelixis&#8217; efforts to build the company as a sustainable business, including repaying remaining debt this summer and assessing in-license opportunities and resuming drug discovery, in order to achieve growth and best in position to help patients and build long-term value; Exelixis&#8217; partnership with Takeda for Japanese commercialization and development of cabozantinib; Exelixis&#8217; collaborations with BMS and Roche for development of cabozantinib in combination with those companies&#8217; respective immunotherapy agents; Exelixis&#8217; expectation that the second interim analysis of the CELESTIAL trial in advanced HCC will be completed in the second half of 2017; Exelixis&#8217; intention to continue pressing its position in the arbitration against Genentech to obtain a just resolution; the likelihood that Exelixis-discovered compounds will be the subject of 13 presentations at the 2017 ASCO Annual Meeting; and Exelixis&#8217; guidance for 2017 total costs and operating expenses, including non-cash costs and expenses. Words such as &#8220;focused,&#8221; &#8220;opportunity,&#8221; &#8220;priority,&#8221; &#8220;continue,&#8221; &#8220;sustain,&#8221; &#8220;potential,&#8221; &#8220;planned,&#8221; &#8220;intent,&#8221; &#8220;anticipated,&#8221; &#8220;will,&#8221; &#8220;eligible,&#8221; &#8220;guidance,&#8221; &#8220;committed,&#8221; or other similar expressions identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements are based upon Exelixis&#8217; current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: the degree of market acceptance of </font></div><div><br></div><div><div style="line-height:120%;padding-left:30px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CABOMETYX, COMETRIQ, and COTELLIC and the availability of coverage and reimbursement for these products; the risk that unanticipated developments could adversely affect the commercialization of CABOMETYX, COMETRIQ, and COTELLIC; Exelixis&#8217; dependence on its relationship with&#160;its collaboration partners, including, the level of their investment in the resources necessary to successfully commercialize cabozantinib and cobimetinib in the territories where they are approved; risks and uncertainties related to regulatory review and approval processes and Exelixis&#8217; compliance with applicable legal and regulatory requirements;&#160;Exelixis&#8217; ability and the ability of its collaborators to conduct clinical trials of cabozantinib and cobimetinib both alone and in combination with other therapies sufficient to achieve a positive completion; risks related to the potential failure of cabozantinib and cobimetinib, both alone and in combination with other therapies, to demonstrate safety and efficacy in clinical testing; the level of costs associated with Exelixis&#8217; commercialization, research and development and other activities; Exelixis&#8217; dependence on its relationship with Genentech/Roche&#160;with respect to cobimetinib and Exelixis&#8217; ability to maintain its rights under the collaboration; Exelixis&#8217;&#160;dependence on third-party vendors; Exelixis&#8217; ability to protect the company&#8217;s intellectual property rights; market competition; changes in economic and business conditions, and other factors discussed under the caption &#8220;Risk Factors&#8221; in Exelixis&#8217; annual report on Form 10-K filed with the&#160;Securities and Exchange Commission (SEC) on&#160;February 27, 2017, and in Exelixis&#8217; future filings with the&#160;SEC, including, without limitation, Exelixis&#8217; quarterly report on Form 10-Q expected to be filed with the SEC on May 1, 2017. The forward-looking statements made in this press release speak only as of the date of this press release.&#160;Exelixis&#160;expressly disclaims any duty, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Exelixis&#8217; expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Exelixis, the Exelixis logo, COMETRIQ and COTELLIC are registered U.S. trademarks, and CABOMETYX is a U.S. trademark.</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-see attached financial tables-</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font></div><div><br></div><div><div style="line-height:120%;padding-left:30px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in thousands, except per share data)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(unaudited)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net product revenues</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,877</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,099</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaboration revenues</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,010</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,328</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,887</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,427</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of goods sold</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,203</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">685</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,210</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,926</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,260</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,857</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restructuring charge</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,701</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,562</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from operations</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,186</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(49,135</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other expense, net:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest income and other, net</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,068</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">202</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,420</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,290</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total other expense, net</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,352</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,088</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) before income taxes</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,834</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(59,223</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">134</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,700</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(59,223</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per share, diluted</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.05</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.26</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares used in computing basic net income (loss) per share </font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">290,870</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,304</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares used in computing diluted net income (loss) per share </font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">309,535</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,304</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED BALANCE SHEET DATA</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in thousands)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(unaudited)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;text-indent:2px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016 </font><font style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and investments </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">475,774</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">479,554</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Working capital</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">265,663</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200,215</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">586,980</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">595,739</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stockholders&#8217; equity</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119,750</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,318</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">_______________________________________</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:inherit;font-size:9pt;">&#32;(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Derived from the audited consolidated financial statements.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><font style="font-family:inherit;font-size:9pt;">&#32;(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and investments include cash and cash equivalents, short- and long-term investments and long-term restricted cash and investments. Long-term restricted cash and investments totaled </font><font style="font-family:inherit;font-size:9pt;">$4.2 million</font><font style="font-family:inherit;font-size:9pt;">&#32;as of both </font><font style="font-family:inherit;font-size:9pt;">March&#160;31, 2017</font><font style="font-family:inherit;font-size:9pt;">&#32;and </font><font style="font-family:inherit;font-size:9pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:9pt;">. </font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"># # #</font></div><div><br></div><div><div style="line-height:120%;padding-left:30px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>exellogo2017q1.gif
<TEXT>
begin 644 exellogo2017q1.gif
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MD$F>D4R>D4J@DDV@DDZAE%&BE5*DEU2CEE*DF%6DF%JFF5JHFUVHFUVHG'^
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MC.(HZ+#'+OOLM-=N^^VXYZ[[[KSW[OOO"&7SQANR#,3,&W*T,Q D;]11CT"
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MI2YWR<M>^O*7P RF,(=)S&(:\YC(3*8RE\G,9CH$*(PXR$GR]8].;64@\!B
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MI06P( 8CI"008;RJ!8S A"$*(9!\%+8%JB@&(UYE4X.L(P$#T.A!W+,P:1A
M @GA!PG(2A 'O8Y,T=06>P5"*101I+ =RLP)^*0.%N3U'Y[P2D& 0C7!+B6S
M)_"!(6  (A'MXS\=&.\<C$I>@<B )XE(! E ( '+#N0_'L"N0(9*D'Q<3;\D
M;@$A"-&" 1A :?;860^$48D-[(P4 L&&K0JRV,T=A+<(P6N^*$6"4Y "!CN3
MP4 @3)!.B4D=T7I #@SQ@Q"XX_\?W>U9"W*PB4TL-@:R^I#3.)N#&5S&7"'
M1"AX,( $ !0 *SA(/@AMV),2 LS#J*9LWPH 'B"D&(OPIV'-F1 %$^09#$B
M(4*QV!:PA1\HQH0P,!&M!8<E! /@02A\(P%\>OC6N,ZUKOEZCL3N^M<$@?4#
M6B"GS + P9(;<@Z(,P!D'PG*!%$7L@TB#:+QY*4#2?)G$(")U0HD,XIH"#]&
M4 !H$,0F^)3  /1"'+T)9"?Y.<G""'*DW@H- .OF"@ 24"T=: 9@ZI:5*@"
M,X&XIP4GZPJJ@!U8>"2B!218S,G@@0D:G. $.3C%:O.!"8CG@)["4,$B"'*.
M1+R !"W_2(0Z/CUBE/\@: 2I!B&451!^_* %WA@(*0@!48+ HQ J4 $AQ@$W
M<9Z !^YN+R,\7E:)I(,0-CW'S#]-"'O_7 4IA\<I".$HF2-[%(2 N4#< 75O
M,_SL:$^[VB%R#D2,TZL#690'YD[WIL/9!J]B@ WT2Q!IP.!5!@A!B_]Q#A^H
M&Z,U6+E JD'WQGL !*_K<2+P>K4<9$T8,.#7>!@A56FT  %7(T1B8>!X#\!B
M(J;@B3"J@>VUNSXB!E@/0:2, ,47Q%4 Z-!_H#T0',C^(*<83RHHOK,?K!8>
MC##  >PN$&+\1B'V4$'&U'&,(TF@]0-9!,%/%BUW"Q@ QS@(_S8@ (!Y0T3;
M6>/'*00J@0,H-=L[,@ +?/WZ^MO__IR#A?1-E(#8\ZA=\$ (KU)H(,(3F$!_
M^)> S/0,R?(/&W "- $ F6 /.= =\)  E@8IJO4 (0 /R' >/W%/U5!3"EB"
MSF0/_W$"9L<00$$"V&>",&A,<[412),#;S07_4 FR(( /S!D/OB#0 B$-P<S
M[Q>#1O@069$#*]@1F4%4;^$MQD$Q$:$N &!K1RA8AG "I) /]J *)_ 2"J$"
M#+ /Q3  T'$..> !-O :3]%S2,$7'H /]L!0\/4/2+,9.)  MM<14,@S4O@U
M/# #'=80ZD "#56 TF(B:E%0"5$)(?_PB#;#'PFP 2%@;P?19H_8-(FXB:%1
M7PAQ"H^X :"'+ *PB(\8 I$7$2T0 AL0>](R'B$@-@BA"B'@ 1)@)YNX )0H
M> DA4+7HBK#R !YP E8X$,+PB-:&+,(8 IGP$*'@ * A "I0"<>@#AYX"3
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MJ(F*!110!1Q:I8$T2 71#VU  1AP 16P"@;12( T$'9 0%IP"_K0$(Y 0)&
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M_P#&(,"K/=S'?OS'@,RM\+ KYSH0C0  -4H02?])QFDQ *D8*AHP 'KCG1N
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M #ECCQ:00BGY8 0 'O"C'   !AL P#,.8@@ X$ @V+B*,"#R _\ - @TH7B
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MA2GXC+@>!+UA=PNQ*>U!1MK@(41AP X1HI!&="0?V\6OAX="68$T$-CP>,
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MIW;H'I,+!M[FSI"&J.5@ABC:S@!ICQBPKW:,L : L?:,LEZ(L\X,D)@)K$@
MU*;GGW",J.L*+2N-\!6)%FAA1J)._P+K#OVKCJ*3AGI8@!60K0[.@1;:3B+&
MU\:0!I^H;,\X!)HP :)VC'*V 57 [NS6;E4@!4, 2=!N#-$F[<XP;74:C2U%
M"^> :\T@!8!>[845C19(@'QX!B.%,4,X(G=@6?&XCJR,+W[ !!C( 0E*(/V
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MN^I7SWJ_*T(A@J@#V39)  /&DP^B'*,@^?#  -1AZ>G\0QH#2('<KW4.HN1
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MRXGR/TS$W;HA@<! (G")! 1C(JL"(R0F2$[H PC@1BB$$_^# 71P08S+K'0
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M091B<M"H(3 "*>0F2IC"3[8(#@2(/:C ')#"*?S'!;L#_OY#67< 4NLY?4P
MEH$"O%0#ETAI-6 #-B!#(@2SGA%$,A_$?^QV1<H8EET")-T#"TB SL* ]RHL
MIF6$1(S:4\" JRL(2]#_&5&@,YUBPS5@PS,P0DZT@$"3NZ?Z;CZD&E$+&0X:
MJ;#KQP H0+ARR9$+&9!11C,?=(V5&NV=@[]B1*K%\(X&Z- !/#]0QC<']\4E
M6Y-1H#UH  "D.P1'1BEJ&3RX0$/X ",(F8#_B4 $/']H"2!_G %< T;X-4%4
M P"$@$T5M>A!1%R+>7SRG9:R'P!D@GPW@ &$*P X@):10@%(@'(;!"4+>"H
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61I0XD6)%BQ<Q9M2XD6-'CQ\]!@0 .P$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
